Actinomycosis (ICD-11: 1C10): Complete Guide for Coding and Diagnosis

1. Introduction

Actinomycosis is a chronic bacterial infectious disease that represents a significant diagnostic challenge for healthcare professionals worldwide. Characterized by its insidious course and varied clinical manifestations, this condition is caused primarily by anaerobic or microaerophilic bacteria of the genera Actinomyces, Propionibacterium and Bifidobacterium, with Actinomyces israelii being the most common etiologic agent, followed by A. gerencseriae.

This infection presents a peculiar characteristic: the causative agents are part of the normal microbiota of the oral cavity, gastrointestinal tract, and female genitourinary tract. The disease develops only when there is disruption of mucosal barriers, allowing these microorganisms to invade deeper tissues. The most frequent clinical forms are cervicofacial (mandibular), thoracic, and abdominopelvic, although any organ may be affected.

The clinical importance of actinomycosis lies in its potential to mimic other more serious conditions, including malignant neoplasms and tuberculosis, often leading to delayed diagnoses and inadequate treatments. The exact prevalence is difficult to determine due to underdiagnosis, but the condition is considered rare in the era of modern antibiotics, most commonly affecting adults between 20 and 60 years of age, with slight male predominance.

Precise coding of actinomycosis in the ICD-11 system is fundamental for epidemiological surveillance, healthcare resource planning, adequate procedure reimbursement, and clinical research. The correct code enables case tracking, trend analysis, and development of evidence-based treatment guidelines, in addition to facilitating communication among healthcare professionals in different clinical contexts.

2. Correct ICD-11 Code

Code: 1C10

Description: Actinomycosis

Parent category: Other bacterial diseases (1C0Y)

Official definition: Actinomycosis is classified as a chronic infectious disease, most frequently localized in the mandible, thorax, or abdomen, in which fermentative actinomycetes of the genera Actinomyces (especially A. israelii and A. gerencseriae), Propionibacterium, and Bifidobacterium act as the primary pathogens.

Code 1C10 was established in ICD-11 to specifically capture cases of true actinomycosis, clearly distinguishing it from other bacterial infections and related conditions such as actinomycetoma. This code is applicable regardless of the anatomical location of the infection, whether cervicofacial, thoracic, abdominal, pelvic, cutaneous, or in the central nervous system.

The hierarchical structure of ICD-11 positions this code within the chapter of infectious diseases, specifically in the section of other bacterial diseases, reflecting its bacterial nature and its distinctive character in relation to more common infections. This classification facilitates the retrieval of epidemiological data and the comparison of incidence between different populations and health systems.

It is important to emphasize that code 1C10 has subcategories that allow for additional specification when necessary, although the main code is sufficient for most clinical records. Adequate documentation of the anatomical location and the bacterial species identified should accompany the coding to maximize the utility of the recorded data.

3. When to Use This Code

The code 1C10 should be used in specific clinical situations where the diagnosis of actinomycosis has been confirmed or is highly probable. Below are detailed practical scenarios:

Scenario 1: Cervicofacial Actinomycosis A patient presents with a hardened, painless mass in the mandibular region with evolution over several weeks, subsequently developing cutaneous fistulas with drainage of purulent material containing yellowish granules ("sulfur granules"). Biopsy or culture identifies Actinomyces israelii. This is the classic scenario for using code 1C10, representing approximately half of all actinomycosis cases. The history frequently reveals recent dental trauma, tooth extraction, or poor oral hygiene.

Scenario 2: Thoracic Actinomycosis Patient with chronic cough, low-grade fever, weight loss, and chest pain. Chest imaging shows pulmonary lesion with extension to the chest wall, simulating malignant neoplasm. Biopsy or CT-guided aspiration identifies Actinomyces spp. with characteristic granulomatous inflammation. Code 1C10 is appropriate even when the initial presentation suggests lung cancer. There is frequently a history of aspiration or periodontal disease.

Scenario 3: Abdominopelvic Actinomycosis Woman with long-term intrauterine device (IUD) presents with chronic abdominal pain, pelvic mass, and intermittent fever. Surgical investigation reveals tubo-ovarian abscess with extension to adjacent structures. Culture or histopathology confirms Actinomyces. Code 1C10 is correct, especially when there is a history of prolonged IUD use, which is a well-established risk factor for pelvic actinomycosis.

Scenario 4: Central Nervous System Actinomycosis Patient develops brain abscess or intracranial expansile lesion with atypical characteristics on neuroimaging. Stereotactic aspiration or surgical resection identifies Actinomyces. Code 1C10 applies even in this rare location, which usually results from hematogenous dissemination or direct extension from a cervicofacial focus.

Scenario 5: Primary Cutaneous Actinomycosis Following penetrating trauma or human bite, a chronic cutaneous lesion develops with abscess formation, fistulas, and progressive fibrosis. Culture of secretion or biopsy identifies Actinomyces. Code 1C10 is appropriate when the infection is limited to skin and subcutaneous tissue without evidence of systemic dissemination.

Scenario 6: Histopathologic Diagnosis without Culture Isolation In situations where culture is negative or was not performed, but histopathologic examination demonstrates typical characteristics including Actinomyces granules, suppurative and granulomatous inflammation, and special stains (PAS, Grocott) confirm branched bacterial filaments, code 1C10 is still appropriate, given that culture isolation is difficult and frequently unsuccessful.

4. When NOT to Use This Code

It is essential to distinguish situations where code 1C10 should not be applied, avoiding coding errors that may compromise medical records and epidemiological data:

Actinomycetoma (Eumycetoma): This condition should be coded separately. Actinomycetoma is a chronic subcutaneous infection caused by different species of actinomycetes (mainly Nocardia, Actinomadura, and Streptomyces), clinically distinct from actinomycosis. It is characterized by the classic triad of tumefaction, multiple fistulas, and grains, generally affecting lower extremities following trauma with contaminated plant material. This is a granulomatous condition with a different dissemination pattern and requires specific coding.

Colonization by Actinomyces without Disease: The presence of Actinomyces in cervical smears of women using IUD, or in sputum samples without clinical or radiological evidence of active infection, represents colonization and not disease. Do not use code 1C10 in these cases. Simple microbiological identification without clinical correlation does not justify the diagnosis of actinomycosis.

Nocardiosis: Although Nocardia is taxonomically related to Actinomyces, nocardiosis is a distinct clinical entity with different epidemiological behavior, clinical manifestations, and treatment. Nocardia primarily causes pulmonary infection in immunosuppressed patients with potential dissemination to the central nervous system. This condition has its own code and should not be classified as 1C10.

Other Mimicking Bacterial Infections: Conditions such as tuberculosis, infections by atypical mycobacteria, abscesses caused by other anaerobic bacterial agents, and even neoplasms with bacterial superinfection should not be coded as actinomycosis without specific microbiological or histopathological confirmation. Clinical or radiological similarity is not sufficient.

Suspected Diagnosis Only: When there is only clinical suspicion of actinomycosis without adequate diagnostic confirmation, appropriate coding for the symptom or syndrome presented should be used, awaiting confirmation to apply code 1C10. Premature coding may lead to inaccurate records.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The diagnosis of actinomycosis requires a combination of clinical, microbiological, and histopathological criteria. Initially, evaluate the clinical presentation: chronic progressive disease (weeks to months), formation of hardened mass, development of fistulas with purulent drainage, and presence of sulfur granules (yellowish masses composed of bacterial colonies).

Confirm through complementary tests: culture in anaerobic medium (although often negative due to the fastidious nature of the organism), histopathological examination showing basophilic granules with radiating eosinophilic border (sunburst appearance), and special stains (Gram, PAS, Grocott) demonstrating branching Gram-positive bacterial filaments.

Diagnostic imaging (computed tomography, magnetic resonance imaging) typically shows mass with heterogeneous enhancement, extension across tissue planes without respecting anatomical barriers, and possible involvement of adjacent bone. These findings, although nonspecific, support the diagnosis when combined with other criteria.

Step 2: Verify Specifiers

Identify the primary anatomical location (cervicofacial, thoracic, abdominal, pelvic, cutaneous, or disseminated), as this influences prognosis and treatment. Document the duration of symptoms, disease severity (localized versus disseminated), presence of complications (fistulas, bone involvement, extension to vital organs), and bacterial species when identified.

Assess present risk factors: dental trauma, recent oral procedures, aspiration, intrauterine device use, immunosuppression, diabetes mellitus, or history of penetrating trauma. These data contextualize the diagnosis and aid in therapeutic planning.

Step 3: Differentiate from Other Codes

1C11 - Bartonellosis: Infection caused by Bartonella spp., presenting as Oroya fever (acute phase with hemolytic anemia) or Peruvian wart (chronic phase with vascular cutaneous lesions). Completely distinct from actinomycosis in etiology, clinical manifestations, and epidemiology. There is no formation of sulfur granules or transmural extension pattern characteristic of actinomycosis.

1C12 - Pertussis: Acute respiratory infection by Bordetella pertussis, characterized by paroxysmal cough with inspiratory whoop, mainly in children. Acute disease, highly contagious, without formation of masses or abscesses. Differentiation is clear by clinical presentation, temporal course, and etiological agent.

1C13 - Tetanus: Neurological disease caused by Clostridium tetani toxin, manifesting with muscle spasms, trismus, and generalized rigidity. It is not an invasive abscess-forming infection. The distinction is evident by the characteristic clinical syndrome and absence of suppurative lesions.

Step 4: Required Documentation

Record in detail: date of symptom onset, precise anatomical location, description of physical findings (masses, fistulas, drainage), results of microbiological cultures with methods used, complete histopathological report including special stains, imaging findings with radiological interpretation, identified risk factors, and instituted treatment.

Document justification for diagnosis when culture is negative, based on characteristic histopathological and clinical findings. Include differential diagnoses considered and reasons for exclusion. This robust documentation supports coding 1C10 and facilitates continuity of care.

6. Complete Practical Example

Clinical Case

A 45-year-old male patient, farmer, presents to the health service with a complaint of progressive swelling in the right submandibular region for approximately three months. He reports that he initially noticed a small hardened, painless nodule that gradually grew, becoming firmer and developing areas of softening. In the last two weeks, two small openings appeared in the overlying skin, draining thick yellowish purulent material.

Medical history reveals extraction of the right lower molar four months ago, with apparently normal healing. Denies significant fever, but reports occasional night sweats and unintentional weight loss of approximately five kilograms. No known comorbidities, does not use regular medications, denies smoking, but admits to irregular oral hygiene.

Physical examination reveals a hardened mass of approximately 6x4 cm in the right submandibular region, with "woody" consistency, adherent to deep planes, with two cutaneous fistulas draining purulent secretion. No significant cervical lymphadenopathy. Oral cavity examination shows poor dental hygiene with multiple cavities. Remainder of physical examination without relevant findings.

Cervical computed tomography demonstrates a heterogeneous mass in the right submandibular region with peripheral enhancement, multiple areas of low density suggestive of abscesses, extension to the masseter muscle and mandibular body with possible initial bone erosion. No significant lymphadenopathy.

Incisional biopsy was performed, revealing chronic suppurative and granulomatous inflammatory process with presence of basophilic granules surrounded by neutrophils and radiating eosinophilic border. Gram staining demonstrated branched Gram-positive bacterial filaments. Culture in anaerobic medium, after seven days of incubation, isolated Actinomyces israelii.

Step-by-Step Coding

Criteria Analysis:

Clinical Criteria Present: Chronic progressive disease (three months), hardened cervicofacial mass, fistula formation with purulent drainage, identified risk factor (recent dental extraction, poor oral hygiene).
Microbiological Criteria: Isolation of Actinomyces israelii in anaerobic culture, confirming etiology.
Histopathological Criteria: Presence of characteristic granules with typical morphology ("sulfur granules"), branched Gram-positive filaments, compatible inflammatory pattern.
Imaging Criteria: Mass with compatible characteristics, extension through tissue planes, possible bone involvement.

Code Selected: 1C10 - Actinomycosis

Complete Justification:

The combination of characteristic clinical presentation (chronic cervicofacial mass with fistulas), definitive microbiological confirmation (isolation of A. israelii), typical histopathological findings (granules with characteristic morphology), and presence of known risk factor (recent dental procedure) unequivocally establishes the diagnosis of cervicofacial actinomycosis.

The cervicofacial location is the most common form of actinomycosis, frequently associated with dental trauma or poor oral hygiene, both present in this case. The pattern of transmural extension observed on imaging, not respecting anatomical planes and with possible bone involvement, is characteristic of this infection.

Differential diagnoses considered included cervical tuberculosis (scrofuloderma), malignant neoplasia (squamous cell carcinoma, lymphoma), and atypical mycobacterial infection, all excluded by microbiological and histopathological confirmation of actinomycosis.

Complementary Codes:

Codes may be added to document specific complications if present, such as mandibular bone involvement or extension to adjacent structures, using additional topography codes when necessary to fully capture the extent of disease.

The treatment instituted consisted of high-dose intravenous crystalline penicillin G for four weeks, followed by oral amoxicillin for six to twelve months, with surgical drainage of abscesses when necessary. This prolonged approach is necessary due to the chronic nature of the infection and limited antibiotic penetration into fibrotic tissues.

7. Related Codes and Differentiation

Within the Same Category

1C11 - Bartonellosis: Bartonellosis is caused by bacteria of the genus Bartonella, mainly B. bacilliformis, transmitted by vectors (phlebotomine sandflies). It presents in two distinct phases: Oroya fever (acute phase with severe hemolytic anemia, fever, and malaise) and Peruvian wart (chronic phase with nodular vascular cutaneous lesions). It is completely differentiated from actinomycosis by vector transmission, restricted geographic distribution (Andean regions), acute versus chronic suppurative clinical manifestations, and absence of abscess or fistula formation. Use 1C11 when there is confirmation of Bartonella spp. and compatible clinical manifestations.

1C12 - Pertussis: Respiratory infection caused by Bordetella pertussis, characterized by paroxysmal cough in fits, frequently followed by characteristic inspiratory whoop and post-tussive vomiting. It primarily affects unvaccinated children, with acute to subacute course (weeks). There is no formation of masses, abscesses, or fistulas. Differentiation from thoracic actinomycosis is clear: pertussis is a disease of the upper airways without parenchymal lesions, whereas thoracic actinomycosis forms pulmonary or mediastinal masses with extension to the chest wall. Use 1C12 for paroxysmal cough with microbiological or clinical confirmation of pertussis.

1C13 - Tetanus: Neurological disease caused by the neurotoxin tetanospasmin produced by Clostridium tetani. It manifests with painful muscle spasms, trismus (inability to open mouth), neck rigidity, and opisthotonus. It is not an invasive suppurative infection, but intoxication by bacterial toxin. The portal of entry is frequently a contaminated wound, but there is no significant local infectious process. Completely distinct from actinomycosis by pathophysiology (toxin versus bacterial invasion), clinical manifestations (neurological versus suppurative), and absence of abscess formation. Use 1C13 for clinical syndrome compatible with tetanus.

Differential Diagnoses

Tuberculosis: Can mimic actinomycosis, especially thoracic and cervical forms (scrofuloderma). Differentiate through culture for mycobacteria, molecular testing (PCR), and histopathology showing caseating granulomas versus Actinomyces granules. Tuberculosis generally presents with more prominent lymphadenopathy.

Nocardiosis: Caused by Nocardia spp., primarily affects lungs in immunosuppressed patients with dissemination to the central nervous system. Differentiated by modified Ziehl-Neelsen staining (weakly acid-fast resistant), aerobic culture (versus anaerobic), and different clinical pattern.

Malignant Neoplasms: Carcinomas and lymphomas can present with masses with central necrosis simulating actinomycosis. Differentiation requires biopsy with histopathological confirmation. Actinomycosis is frequently initially diagnosed as neoplasia.

8. Differences with ICD-10

In ICD-10, actinomycosis was coded as A42, with specific subdivisions for different anatomical locations:

A42.0: Pulmonary actinomycosis
A42.1: Abdominal actinomycosis
A42.2: Cervicofacial actinomycosis
A42.7: Septicemic actinomycosis
A42.8: Other forms of actinomycosis
A42.9: Actinomycosis, unspecified

The transition to ICD-11 with code 1C10 represents a significant simplification. While ICD-10 required mandatory specification of anatomical location through subcodes, ICD-11 uses a single main code (1C10) with the possibility of additional specification through extensions when necessary, but not mandatory for basic coding.

This change reflects ICD-11's philosophy of simplifying primary coding while maintaining the capacity for detailed specification through a post-coordinated extension system. It allows for more flexible documentation, reducing coding errors from incorrect subcategory selection.

Practical impact: professionals accustomed to ICD-10 must adapt to the single code 1C10, documenting anatomical location in free text or through extensions when the system allows. This facilitates coding in situations of multifocal or disseminated disease, where multiple ICD-10 codes would be necessary.

For purposes of longitudinal epidemiological comparison, it is important to adequately map codes A42.x (ICD-10) to 1C10 (ICD-11), maintaining traceability of historical data. Health information systems should implement correspondence tables to ensure continuity of time series.

9. Frequently Asked Questions

1. How is a definitive diagnosis of actinomycosis made?

Definitive diagnosis requires a combination of clinical, microbiological, and histopathological criteria. Clinically, suspicion arises in chronic progressive disease with mass formation, abscesses, and fistulas. Microbiologically, the gold standard is isolation of Actinomyces spp. in anaerobic culture, although this is achieved in only 50-70% of cases due to the fastidious nature of the organism. Histopathologically, identification of sulfur granules (bacterial colonies) with characteristic morphology on biopsy is highly specific. In practice, many cases are diagnosed by histopathology when culture is negative or was not performed.

2. Is treatment available in public health systems?

Yes, the primary treatment for actinomycosis is prolonged antibiotic therapy with penicillins, medications generally available in public health systems worldwide. Intravenous crystalline penicillin G in high doses is used initially (hospital phase), followed by oral penicillin or amoxicillin for a prolonged period (six to twelve months or longer). For patients allergic to penicillins, alternatives include tetracyclines, erythromycin, or clindamycin. Surgical procedures for abscess drainage or resection of necrotic tissue may be necessary and are also available in general surgical services.

3. How long does treatment last?

Antibiotic treatment of actinomycosis is notoriously prolonged, typically lasting six to twelve months, and may extend to eighteen months in complex cases. The initial phase generally consists of intravenous antibiotic therapy for two to six weeks, followed by prolonged oral therapy. The exact duration depends on anatomical location (cervicofacial forms may respond more rapidly than thoracic or abdominal forms), disease extent, clinical response, and presence of complications. Prolonged treatment is necessary due to limited antibiotic penetration into fibrotic tissues and avascular areas characteristic of this infection.

4. Can this code be used in medical certificates and official documents?

Yes, code 1C10 can and should be used in medical certificates, hospital discharge reports, disability benefit requests, and other official medical documents when the diagnosis of actinomycosis is confirmed. Appropriate documentation should include not only the code but also description of anatomical location, severity, and functional impact of the disease. For purposes of work leave, actinomycosis frequently justifies prolonged periods of medical leave, especially during the hospital phase of intravenous treatment and when there is significant functional impairment.

5. Is actinomycosis contagious?

No, actinomycosis is not a contagious or transmissible disease between people. The causative agents (Actinomyces spp.) are part of normal human microbiota, residing in the oral cavity, gastrointestinal tract, and genitourinary tract. Disease develops when there is disruption of mucosal barriers allowing deep tissue invasion, usually after trauma, surgery, or in the presence of a foreign body. There is no need for patient isolation or special contact precautions. Family members and contacts do not have increased risk of developing actinomycosis.

6. What are the main risk factors for developing actinomycosis?

The main risk factors include: poor oral hygiene and periodontal disease (for cervicofacial form), invasive dental procedures or facial trauma, aspiration of oral contents (for pulmonary form), abdominal surgery or intestinal perforation (for abdominal form), prolonged use of intrauterine device especially for more than two years (for pelvic form), diabetes mellitus, immunosuppression, alcoholism, and penetrating trauma. Recognizing these factors aids in early diagnostic suspicion in patients with compatible clinical presentations.

7. Can actinomycosis recur after treatment?

Yes, recurrences can occur, especially when antibiotic treatment is discontinued prematurely or when predisposing factors are not corrected. Recurrence rate varies but is estimated at 10-20% of treated cases. To minimize recurrence risk, it is essential to complete the full course of antibiotic therapy (even when there is apparent clinical improvement), perform adequate surgical drainage of collections when indicated, correct predisposing factors (improve oral hygiene, remove IUD, treat periodontal disease), and maintain regular clinical follow-up for a prolonged period after completion of treatment.

8. How to differentiate actinomycosis from cancer in initial evaluation?

This is a crucial clinical question, as actinomycosis frequently mimics malignant neoplasms in clinical presentation and imaging studies. Characteristics that may suggest actinomycosis include: history of dental trauma or recent invasive procedure, presence of fistulas draining purulent material (uncommon in primary neoplasms), identification of sulfur granules in secretions, absence of significant lymphadenopathy (common in cancers), and pattern of extension through tissue planes without respecting anatomical barriers (neoplasms generally respect fasciae initially). However, definitive differentiation requires biopsy with histopathological and microbiological examination. Many cases of actinomycosis are initially treated as neoplasm until diagnostic confirmation.

Conclusion:

Actinomycosis represents a significant diagnostic challenge due to its relative rarity, insidious chronic course, and ability to mimic other serious conditions. Correct coding using 1C10 in ICD-11 is fundamental for appropriate record-keeping, planning of appropriate treatment, and epidemiological surveillance. Healthcare professionals should maintain a high index of suspicion in patients with chronic masses, abscesses, and fistulas, especially when identifiable risk factors are present. Early diagnosis and appropriate prolonged antibiotic treatment result in excellent prognosis in most cases, avoiding significant morbidity and extensive surgical procedures.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Actinomycosis

Partager